EUVIMEDEUVIMED entdecken
Crossref

Exploring 2‐Thioxo‐1,2,3,4‐tetrahydropyrimidines as Dual Acting GSK‐3β/Aβ Aggregation Inhibitors: Implications for Alzheimer's Disease Treatment

Sukanya Sukanya iD, Aina Bellver-Sanchis, Bhanwar Singh Choudhary iD, Sunil Kumar, Belén Pérez, Antón Leandro Martínez Rodríguez, Jose Brea, Carmen Escolano iD, Christian Griñán-Ferré iD, Ruchi Malik iD

Drug Development Research · 2025-06 · 86 (4)

DOI: 10.1002/ddr.70112 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, online erschienen am 16.06.2025. Verfasst von Sukanya Sukanya und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Central University of Rajasthan, Bandarsindari, Ajmer, Rajasthan, India. Hauptthemen laut MEDLINE: Glycogen Synthase Kinase 3 beta, Alzheimer Disease, Pyrimidines, Amyloid beta-Peptides. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The etiology of Alzheimer's disease (AD) is complex and multifactorial. There is a pressing need for therapies that can prevent or slow AD progression. Consequently, drug development has shifted from single‐target approaches to multi‐faceted strategies that emphasize early intervention rather than late‐stage treatment. One promising target is glycogen synthase kinase‐3β (GSK‐3β), an enzyme implicated in tau hyperphosphorylation and Aβ plaque formation. Based on our earlier work, we synthesized 25 2‐thioxo‐1,2,3,4‐tetrahydropyrimidine derivatives designed as GSK‐3β inhibitors, tau phosphorylation inhibitors, and Aβ accumulation. Two compounds emerged as particularly effective: compound 63 (IC 50 = 1.69 µM) and compound 66 (IC 50 = 0.90 µM), with compound 66 identified as an ATP‐competitive inhibitor of GSK‐3β. Further pharmacokinetic studies and in vitro drug metabolism assessments were conducted, followed by in vivo efficacy studies using Caenorhabditis elegans . Notably, these compounds reduced phosphorylated tau levels in the BR5706 strain and decreased Aβ aggregate deposition in the CL2006 strain. Molecular Dynamic (MD) simulations were also performed on both compounds. These findings provide valuable insights into GSK‐3β drug development and highlight the potential of these inhibitors as therapeutic candidates for AD by targeting both tau and Aβ, the two pathological hallmarks of AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glycogen Synthase Kinase 3 betaAlzheimer DiseasePyrimidinesAmyloid beta-PeptidesAnimalsHumanstau ProteinsCaenorhabditis elegansPhosphorylation

Stichwörter der Autor:innen

Aβ accumulationGSK‐3βMD simulationalzheimer's Diseasetau phosphorylation

Substanzen

Glycogen Synthase Kinase 3 betaPyrimidinesAmyloid beta-Peptidestau Proteins

Autor:innen und Institutionen

  • Department of Pharmacy, Central University of Rajasthan, Bandarsindari, Ajmer, Rajasthan, India.
  • Pharmacology Section, Department of Pharmacology, Toxicology, and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, Institute of Neuroscience, University of Barcelona (NeuroUB), Barcelona, Spain.
  • Department of Pharmacology Therapeutics and Toxicology, Institute of Neuroscience, Autonomous University of Barcelona, Barcelona, Spain.
  • Innopharma Screening Platform, Biofarma Research Group. Centro de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS), Department of Pharmacology, Pharmacy and Pharmaceutical Technology, University of Sa…
  • Health Research, Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Santiago de Compostela, Spain.
  • Laboratory of Medicinal Chemistry (Associated Unit to CSIC), Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, Institute of Biomedicine (IBUB), University of Barcelon…

ORCID-Profile: Sukanya Sukanya, Bhanwar Singh Choudhary, Carmen Escolano, Christian Griñán-Ferré, Ruchi Malik

Zitieren

APA

Sukanya, S., Bellver-Sanchis, A., Choudhary, B. S., Kumar, S., Pérez, B., Rodríguez, A. L. M., Brea, J., Escolano, C., Griñán-Ferré, C., & Malik, R. (2025). Exploring 2‐Thioxo‐1,2,3,4‐tetrahydropyrimidines as Dual Acting GSK‐3β/Aβ Aggregation Inhibitors: Implications for Alzheimer's Disease Treatment. Drug Development Research, 86(4). https://doi.org/10.1002/ddr.70112

Vancouver

Sukanya S, Bellver-Sanchis A, Choudhary BS, Kumar S, Pérez B, Rodríguez ALM, et al. Exploring 2‐Thioxo‐1,2,3,4‐tetrahydropyrimidines as Dual Acting GSK‐3β/Aβ Aggregation Inhibitors: Implications for Alzheimer's Disease Treatment. Drug Development Research. 2025;86(4). doi:10.1002/ddr.70112

BibTeX
@article{Sukanya2025,
  author = {Sukanya, Sukanya and Bellver-Sanchis, Aina and Choudhary, Bhanwar Singh and Kumar, Sunil and Pérez, Belén and Rodríguez, Antón Leandro Martínez and Brea, Jose and Escolano, Carmen and Griñán-Ferré, Christian and Malik, Ruchi},
  title = {Exploring 2‐Thioxo‐1,2,3,4‐tetrahydropyrimidines as Dual Acting GSK‐3β/Aβ Aggregation Inhibitors: Implications for Alzheimer's Disease Treatment},
  journal = {Drug Development Research},
  year = {2025},
  volume = {86},
  number = {4},
  doi = {10.1002/ddr.70112}
}
Kostenlos starten →